⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83583 | 0.93 | — | — | |
| SCHEMBL11266324 | 0.93 | — | — | |
| SCHEMBL83584 | 0.93 | — | — | |
| SCHEMBL11584052 | 0.88 | — | — | |
| SCHEMBL3499180 | 0.82 | — | — | |
| SCHEMBL944499 | 0.82 | — | — | |
| SCHEMBL5984389 | 0.82 | — | — | |
| SCHEMBL5985927 | 0.82 | — | — | |
| SCHEMBL1677328 | 0.81 | — | — | |
| SCHEMBL1677325 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865094-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116271053-A | Treatment and diagnosis of melanoma | 洛克菲勒大学 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-3626309-B1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | UNIV ROCKEFELLER (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-110037999-B | Treatment and diagnosis of melanoma | 洛克菲勒大学（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| US-10945978-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200230090-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3626309-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-1099442-A2 | Methods of administering apo B-secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5658942-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5604256-A | (7-(5-(1,3-DIOXANE-5YL)METHOXYIMINO-2-METHYL-8-(2-METHYLBUTYR -OXY)3-OXO-1,2,3,5,6,7,8,8A-OCTAHYDRO-1-NAPHTHYL)-3-HYDROXY-5 -OXOHEPTANOIC ACID AND SALTS | SANKYO COMPANY, LIMITED (JP) | 1997-02-18 | — | — | US | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0570245-B1 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO CO (JP) | 1996-10-30 | — | — | EP | disclosed |
| US-5403860-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0314435-B1 | OCTAHYDRONAPHTHALENE OXIME DERIVATIVES FOR CHOLESTEROL SYNTHESIS INHIBITION, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Sankyo Company Limited (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4997848-A | Enzyme inhibitors | SANKYO COMPANY, LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0314435-A2 | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them | Sankyo Company Limited (JP) | 1989-05-03 | — | — | EP | disclosed |